Qinlock (ripretinib) is indicated to treat adult patients with advanced gastrointestinal stromal tumors (GIST).
The drug from Qinlock won FDA approval on May 15, 2020.
In the Phase 3 INVICTUS study, the drug demonstrated clinical benefits with dose escalation for patients with advanced gastrointestinal stromal tumors with disease progression.
As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.
Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.
